Treatment  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
rosacea  ||| S:13 E:21 ||| VBG
A  ||| S:21 E:23 ||| DT
range  ||| S:23 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
treatment  ||| S:32 E:42 ||| NN
options  ||| S:42 E:50 ||| NNS
are  ||| S:50 E:54 ||| VBP
available  ||| S:54 E:64 ||| JJ
in  ||| S:64 E:67 ||| IN
rosacea ||| S:67 E:74 ||| NN
,  ||| S:74 E:76 ||| ,
which  ||| S:76 E:82 ||| WDT
include  ||| S:82 E:90 ||| VBP
several  ||| S:90 E:98 ||| JJ
topical  ||| S:98 E:106 ||| NNS
( ||| S:106 E:107 ||| -LRB-
mainly  ||| S:107 E:114 ||| RB
metronidazole ||| S:114 E:127 ||| JJ
,  ||| S:127 E:129 ||| ,
azelaic  ||| S:129 E:137 ||| JJ
acid ||| S:137 E:141 ||| NN
,  ||| S:141 E:143 ||| ,
other  ||| S:143 E:149 ||| JJ
antibiotics ||| S:149 E:160 ||| NN
,  ||| S:160 E:162 ||| ,
sulfur ||| S:162 E:168 ||| NN
,  ||| S:168 E:170 ||| ,
retinoids ||| S:170 E:179 ||| CD
)  ||| S:179 E:181 ||| -RRB-
and  ||| S:181 E:185 ||| CC
oral  ||| S:185 E:190 ||| JJ
drugs  ||| S:190 E:196 ||| NNS
( ||| S:196 E:197 ||| -LRB-
mainly  ||| S:197 E:204 ||| RB
tetracyclines ||| S:204 E:217 ||| JJ
,  ||| S:217 E:219 ||| ,
metronidazole ||| S:219 E:232 ||| NN
,  ||| S:232 E:234 ||| ,
macrolides ||| S:234 E:244 ||| CD
) ||| S:244 E:245 ||| -RRB-
.  ||| S:245 E:247 ||| .
In  ||| S:247 E:250 ||| IN
some  ||| S:250 E:255 ||| DT
cases ||| S:255 E:260 ||| NNS
,  ||| S:260 E:262 ||| ,
the  ||| S:262 E:266 ||| DT
first  ||| S:266 E:272 ||| JJ
choice  ||| S:272 E:279 ||| NN
is  ||| S:279 E:282 ||| VBZ
a  ||| S:282 E:284 ||| DT
systemic  ||| S:284 E:293 ||| JJ
therapy  ||| S:293 E:301 ||| NN
because  ||| S:301 E:309 ||| IN
patients  ||| S:309 E:318 ||| NNS
may  ||| S:318 E:322 ||| MD
have  ||| S:322 E:327 ||| VB
sensitive  ||| S:327 E:337 ||| JJ
skin  ||| S:337 E:342 ||| NN
and  ||| S:342 E:346 ||| CC
topical  ||| S:346 E:354 ||| JJ
medications  ||| S:354 E:366 ||| NN
can  ||| S:366 E:370 ||| MD
be  ||| S:370 E:373 ||| VB
irritant ||| S:373 E:381 ||| NNS
.  ||| S:381 E:383 ||| .
Isotretinoin  ||| S:383 E:396 ||| NNP
can  ||| S:396 E:400 ||| MD
be  ||| S:400 E:403 ||| VB
used  ||| S:403 E:408 ||| VBN
in  ||| S:408 E:411 ||| IN
resistant  ||| S:411 E:421 ||| JJ
cases  ||| S:421 E:427 ||| NNS
of  ||| S:427 E:430 ||| IN
rosacea ||| S:430 E:437 ||| NN
.  ||| S:437 E:439 ||| .
Unfortunately ||| S:439 E:452 ||| RB
,  ||| S:452 E:454 ||| ,
the  ||| S:454 E:458 ||| DT
majority  ||| S:458 E:467 ||| NN
of  ||| S:467 E:470 ||| IN
studies  ||| S:470 E:478 ||| NNS
on  ||| S:478 E:481 ||| IN
rosacea  ||| S:481 E:489 ||| JJ
treatments  ||| S:489 E:500 ||| NNS
are  ||| S:500 E:504 ||| VBP
at  ||| S:504 E:507 ||| IN
high  ||| S:507 E:512 ||| JJ
or  ||| S:512 E:515 ||| CC
unclear  ||| S:515 E:523 ||| JJ
risk  ||| S:523 E:528 ||| NN
of  ||| S:528 E:531 ||| IN
bias ||| S:531 E:535 ||| NN
.  ||| S:535 E:537 ||| .
A  ||| S:537 E:539 ||| DT
recent  ||| S:539 E:546 ||| JJ
Cochrane  ||| S:546 E:555 ||| JJ
review  ||| S:555 E:562 ||| NN
found  ||| S:562 E:568 ||| VBD
that  ||| S:568 E:573 ||| IN
only  ||| S:573 E:578 ||| RB
topical  ||| S:578 E:586 ||| JJ
metronidazole ||| S:586 E:599 ||| NN
,  ||| S:599 E:601 ||| ,
azelaic  ||| S:601 E:609 ||| JJ
acid ||| S:609 E:613 ||| NN
,  ||| S:613 E:615 ||| ,
and  ||| S:615 E:619 ||| CC
oral  ||| S:619 E:624 ||| JJ
doxycycline  ||| S:624 E:636 ||| NNS
( ||| S:636 E:637 ||| -LRB-
40  ||| S:637 E:640 ||| CD
mg ||| S:640 E:642 ||| CD
)  ||| S:642 E:644 ||| -RRB-
had  ||| S:644 E:648 ||| VBD
some  ||| S:648 E:653 ||| DT
evidence  ||| S:653 E:662 ||| NN
to  ||| S:662 E:665 ||| TO
support  ||| S:665 E:673 ||| VB
their  ||| S:673 E:679 ||| PRP$
effectiveness  ||| S:679 E:693 ||| NN
in  ||| S:693 E:696 ||| IN
moderate  ||| S:696 E:705 ||| JJ
to  ||| S:705 E:708 ||| TO
severe  ||| S:708 E:715 ||| JJ
rosacea  ||| S:715 E:723 ||| NN
and  ||| S:723 E:727 ||| CC
concluded  ||| S:727 E:737 ||| VBD
that  ||| S:737 E:742 ||| DT
further  ||| S:742 E:750 ||| JJ
well-designed ||| S:750 E:763 ||| NN
,  ||| S:763 E:765 ||| ,
adequately-powered  ||| S:765 E:784 ||| JJ
randomised  ||| S:784 E:795 ||| NNS
controlled  ||| S:795 E:806 ||| VBN
trials  ||| S:806 E:813 ||| NNS
are  ||| S:813 E:817 ||| VBP
required ||| S:817 E:825 ||| VBN
.  ||| S:825 E:827 ||| .
In  ||| S:827 E:830 ||| IN
our  ||| S:830 E:834 ||| PRP$
practice ||| S:834 E:842 ||| NN
,  ||| S:842 E:844 ||| ,
we  ||| S:844 E:847 ||| PRP
evaluate  ||| S:847 E:856 ||| VB
our  ||| S:856 E:860 ||| PRP$
patients  ||| S:860 E:869 ||| NNS
for  ||| S:869 E:873 ||| IN
the  ||| S:873 E:877 ||| DT
presence  ||| S:877 E:886 ||| NN
of  ||| S:886 E:889 ||| IN
two  ||| S:889 E:893 ||| CD
possible  ||| S:893 E:902 ||| JJ
triggers ||| S:902 E:910 ||| NN
,  ||| S:910 E:912 ||| ,
Helicobacter  ||| S:912 E:925 ||| NNP
pylori  ||| S:925 E:932 ||| JJ
infection  ||| S:932 E:942 ||| NN
and  ||| S:942 E:946 ||| CC
small  ||| S:946 E:952 ||| JJ
intestinal  ||| S:952 E:963 ||| JJ
bacterial  ||| S:963 E:973 ||| JJ
overgrowth ||| S:973 E:983 ||| NN
.  ||| S:983 E:985 ||| .
When  ||| S:985 E:990 ||| WRB
they  ||| S:990 E:995 ||| PRP
are  ||| S:995 E:999 ||| VBP
present  ||| S:999 E:1007 ||| RB
we  ||| S:1007 E:1010 ||| PRP
use  ||| S:1010 E:1014 ||| VBP
adapted  ||| S:1014 E:1022 ||| VBN
antibiotic  ||| S:1022 E:1033 ||| JJ
protocols ||| S:1033 E:1042 ||| NNS
.  ||| S:1042 E:1044 ||| .
If  ||| S:1044 E:1047 ||| IN
not ||| S:1047 E:1050 ||| RB
,  ||| S:1050 E:1052 ||| ,
we  ||| S:1052 E:1055 ||| PRP
use  ||| S:1055 E:1059 ||| VBP
oral  ||| S:1059 E:1064 ||| JJ
metronidazole  ||| S:1064 E:1078 ||| NN
or  ||| S:1078 E:1081 ||| CC
oral  ||| S:1081 E:1086 ||| JJ
tetracycline  ||| S:1086 E:1099 ||| NN
to  ||| S:1099 E:1102 ||| TO
treat  ||| S:1102 E:1108 ||| VB
papulopustolar  ||| S:1108 E:1123 ||| JJ
rosacea ||| S:1123 E:1130 ||| NN
.  ||| S:1130 E:1132 ||| .
We  ||| S:1132 E:1135 ||| PRP
also  ||| S:1135 E:1140 ||| RB
look  ||| S:1140 E:1145 ||| VB
for  ||| S:1145 E:1149 ||| IN
Demodex  ||| S:1149 E:1157 ||| NNP
folliculorum  ||| S:1157 E:1170 ||| JJ
infestation ||| S:1170 E:1181 ||| NN
.  ||| S:1181 E:1183 ||| .
When  ||| S:1183 E:1188 ||| WRB
Demodex  ||| S:1188 E:1196 ||| NNP
concentration  ||| S:1196 E:1210 ||| NN
is  ||| S:1210 E:1213 ||| VBZ
higher  ||| S:1213 E:1220 ||| JJR
than  ||| S:1220 E:1225 ||| IN
5 ||| S:1225 E:1226 ||| CD
/ ||| S:1226 E:1227 ||| CD
cm ||| S:1227 E:1229 ||| NNS
( ||| S:1229 E:1230 ||| -LRB-
2 ||| S:1230 E:1231 ||| LS
)  ||| S:1231 E:1233 ||| -RRB-
we  ||| S:1233 E:1236 ||| PRP
use  ||| S:1236 E:1240 ||| VBP
topical  ||| S:1240 E:1248 ||| JJ
crotamiton  ||| S:1248 E:1259 ||| NN
10 ||| S:1259 E:1261 ||| CD
%  ||| S:1261 E:1263 ||| NN
or  ||| S:1263 E:1266 ||| CC
metronidazole ||| S:1266 E:1279 ||| NN
.  ||| S:1279 E:1281 ||| .
